Genovis
19.44 SEK
+4.97 %
1,632 following
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+4.97 %
+12.37 %
-8.52 %
-8.52 %
-18.32 %
-0.31 %
-70.68 %
-47.10 %
-28.99 %
Genovis operates in biotechnology. The main focus is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to facilitate the LifeScience industry to conduct preclinical research. The company's products are resold under several brands. Genovis was established in 1999 and is headquartered in Lund.
Read moreMarket cap
1.28B SEK
Turnover
550.46K SEK
Revenue
128.95M
EBIT %
16.5 %
P/E
54
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/4
2026
Interim report Q1'26
18/5
2026
General meeting '26
23/7
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Genovis and Plasmidsaurus Introduce SEQguard™ Dino Preserve — Enabling Ambient-Temperature RNA Shipping for Next-Generation Sequencing
Genovis ingår icke-exklusivt licensavtal för EndoS2-enzymteknologi för utveckling och kommersialisering av antikroppskonjugat (ADC)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
